Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
Yamagishi
Takuya
T
Department of Urology, Yokohama City University School of Medicine, Yokohama, Japan.
Uemura
Hiroji
H
Nakaigawa
Noboru
N
Noguchi
Kazumi
K
Kubota
Yoshinobu
Y
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001713:Biphenyl Compounds; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D017211:Treatment Failure
D047228:Angiotensin II Type 1 Receptor Blockers; D018931:Antineoplastic Agents, Hormonal; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D017430:Prostate-Specific Antigen; C081643:candesartan